Online citations, reference lists, and bibliographies.

MiR-134, Epigenetically Silenced In Gliomas, Could Mitigate The Malignant Phenotype By Targeting KRAS

Z. Wang, C. Zhang, Z. Wang, X. Meng, Xiaojuan Liu, B. Han, Chunbin Duan, J. Cai, Zhong-fei Hao, M. Chen, T. Jiang, Y. Li, C. Jiang, Hong-jun Wang
Published 2018 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Gliomas are characterized by a malignant phenotype with proliferation, cell cycle arrest and invasion. To explore the biological consequences of epigenetically regulated miRNAs, we performed a microarray-based screening (whose expression was affected by 5-AZA treatment) followed by bisulfite sequencing validation. We found that miR-134 as an epigenetically regulated suppressor gene with prognostic value in gliomas. MicroRNA-134 was downregulated in high-grade gliomas, especially in GBM samples. Functional studies in vitro and in vivo in mouse models showed that overexpression of miR-134 was sufficient to reduce cell cycle arrest, cell proliferation and invasion. Target analysis and functional assays correlated the malignant phenotype with miR-134 target gene KRAS, an established upstream regulator of ERK and AKT pathways. Overall, our results highlighted a role for miR-134 in explaining the malignant phenotype of gliomas and suggested its relevance as a target to develop for early diagnostics and therapy.
This paper references
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.
B. Raphael (2017)
miR-892b Silencing Activates NF-κB and Promotes Aggressiveness in Breast Cancer.
L. Jiang (2016)
Genetic unmasking of an epigenetically silenced microRNA in human cancer cells.
Amaia Lujambio (2007)
R: A language and environment for statistical computing.
R. Team (2014)
MicroRNA expression profiles classify human cancers
J. Lu (2005)
MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer
Ri Cui (2015)
A brain-specific microRNA regulates dendritic spine development
G. Schratt (2006)
The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer
R. Hilger (2002)
miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells.
Yiyang Liu (2015)
Oncogenic KRAS confers chemoresistance by upregulating NRF2.
S. Tao (2014)
Genome-Wide Screening Identified That miR-134 Acts as a Metastasis Suppressor by Targeting Integrin β1 in Hepatocellular Carcinoma
Ruopeng Zha (2014)
Beta-naphthoflavone (DB06732) mediates estrogen receptor-positive breast cancer cell cycle arrest through AhR-dependent regulation of PI3K/AKT and MAPK/ERK signaling.
C. Wang (2014)
Integrated genomic and molecular characterization of cervical cancer
R. Burk (2017)
A microRNA expression signature of human solid tumors defines cancer gene targets
S. Volinia (2006)
miR‐134 inhibits non‐small cell lung cancer growth by targeting the epidermal growth factor receptor
Q. Qin (2016)
miR-656 inhibits glioma tumorigenesis through repression of BMPR1A.
M. Guo (2014)
MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B.
J. Hu (2016)
Hepatocyte nuclear factor - 4 α reverses malignancy of hepatocellular carcinoma through regulating miR - 134 in the DLK 1 - DIO 3 region
M. Ramachandran (2017)
MicroRNA-134 targets KRAS to suppress breast cancer cell proliferation, migration and invasion.
Xiaomei Su (2017)
MicroRNAs: genomics, biogenesis
D. P. Bartel (2004)
AKT/PKB Signaling: Navigating Downstream
B. Manning (2007)
MiR-134 regulates the proliferation and invasion of glioblastoma cells by reducing Nanog expression
Chao-Shi Niu (2013)
MicroRNA-134 functions as a tumor suppressor gene in gastric cancer.
Ze-An Qiu (2016)
Integrated Molecular Characterization of Uterine Carcinosarcoma.
A. Cherniack (2017)
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
N. Normanno (2009)
DNA methylation of microRNA genes in multiple myeloma.
K. Wong (2012)
MicroRNAs: small RNAs with a big role in gene regulation
L. He (2004)
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
H. Noushmehr (2010)
Evolutionary etiology of high-grade astrocytomas
Y. Song (2013)
MicroRNA-134 modulates glioma cell U251 proliferation and invasion by targeting KRAS and suppressing the ERK pathway
Yuguang Zhao (2016)
STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells.
Maureen M. Sherry (2009)
Genome-Wide DNA Methylation Analysis Reveals Epigenetic Dysregulation of MicroRNA-34A in TP53-Associated Cancer Susceptibility.
Nardin Samuel (2016)
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response
N. Szerlip (2012)
Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus
M. Ramachandran (2016)
MicroRNA‐21 Expression is regulated by β‐catenin/STAT3 Pathway and Promotes Glioma Cell Invasion by Direct Targeting RECK
L. Han (2012)
Understanding high grade glioma: molecular mechanism, therapy and comprehensive management.
Y. Wang (2013)
Hepatocyte nuclear factor‐4α reverses malignancy of hepatocellular carcinoma through regulating miR‐134 in the DLK1‐DIO3 region
C. Yin (2013)
Early Epigenetic Downregulation of microRNA-192 Expression Promotes Pancreatic Cancer Progression.
Sandeep K. Botla (2016)
Mutational landscape and clonal architecture in grade II and III gliomas
H. Suzuki (2015)
miR-181d/MALT1 regulatory axis attenuates mesenchymal phenotype through NF-κB pathways in glioblastoma.
F. Yang (2017)
Upregulation of miR-181s reverses mesenchymal transition by targeting KPNA4 in glioblastoma
H. Wang (2015)
MicroRNA-320a suppresses in GBM patients and modulates glioma cell functions by targeting IGF-1R
Tianzhu Guo (2014)
MicroRNA and Target Protein Patterns Reveal Physiopathological Features of Glioma Subtypes
Elodie Lages (2011)
miR-196b Is Epigenetically Silenced during the Premalignant Stage of Lung Carcinogenesis.
C. Tellez (2016)
RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations
J. Jeuken (2007)
Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma
Y. Zhang (2014)
MicroRNAs Genomics, Biogenesis, Mechanism, and Function
D. Bartel (2004)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar